{
    "clinical_study": {
        "@rank": "31939", 
        "acronym": "CASAF", 
        "brief_summary": {
            "textblock": "The study is aimed at testing the hypothesis whether atrial fibrillary rate (AFR), as a\n      measure of atrial electrical remodeling assessed from surface ECG, is predictive of sinus\n      rhythm maintenance after electrical cardioversion.\n\n      Earlier studies performed in a retrospective fashion suggested that high AFR exceeding\n      350-360 fibrillations per minute is an independent predictor of AF relapse after\n      cardioversion, particularly in patients with duration of AF episode not exceeding 30 days,\n      however this hypothesis has not been tested in a prospective study.\n\n      CASAF is an observational study that will enroll patients with short duration (< 30 days) AF\n      admitted for electrical cardioversion. Admission ECG will be extracted  in a digital format\n      and processed off-line for estimation of AFR. AF relapse will be assessed during 6-weeks\n      long follow-up period during which ECG control will be scheduled at week 1 and 6."
        }, 
        "brief_title": "CArdioversion of Short Duration Atrial Fibrillation", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Electrocardiography", 
            "Electrical Remodeling"
        ], 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrent AF verified by at least one ECG recording prior to the index admission\n\n          -  Known onset of symptoms within 30 days from index admission.\n\n          -  Sinus rhythm ECG within 30 days prior to the index admission If onset of symptoms is\n             unknown.\n\n          -  If duration of the present AF episode >48 hours then thromboembolic risk should be\n             minimized by either verifying that the patient is adequately anticoagulated according\n             to the hospital routine or TEE performed to verify the lack of contraindications for\n             electrical cardioversion.\n\n          -  Echocardiography at any time since first onset of AF to verify the lack of\n             significant valvular disease.\n\n          -  Age older than 18 years.\n\n        Exclusion Criteria:\n\n          -  AF due to reversible cause or significant valvular heart disease\n\n          -  Treatment with class I or III antiarrhythmic drugs within five half-lives of their\n             elimination period. No amiodarone treatment within six months before admission\n\n          -  Prior ablation of AF\n\n          -  Unability to verify onset of symptoms within 30 days prior to the index admission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with recent onset persistent atrial fibrillation admitted for cardioversion"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112318", 
            "org_study_id": "CASAF20090610"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Quebec City", 
                        "country": "Canada", 
                        "zip": "G1V 4G5"
                    }, 
                    "name": "l'Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "sten.e.ostenson@skane.se", 
                    "last_name": "Sten \u00d6stenson, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Kristianstad", 
                        "country": "Sweden", 
                        "zip": "291 85"
                    }, 
                    "name": "Kristianstad General Hospital"
                }, 
                "investigator": {
                    "last_name": "Sten \u00d6stenson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mariambashir@hotmail.com", 
                    "last_name": "Mariam Seifert, MD", 
                    "phone": "+4646173518"
                }, 
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "22185"
                    }, 
                    "name": "Skane University Hospital"
                }, 
                "investigator": {
                    "last_name": "Mariam Seifert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Sweden"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Study of ECG-derived Atrial Fibrillatory Rate for Prediction of the Outcome of Cardioversion of Short Duration Atrial Fibrillation", 
        "overall_contact": {
            "email": "pyotr.platonov@med.lu.se", 
            "last_name": "Pyotr G Platonov, MD, PhD", 
            "phone": "+4646172435"
        }, 
        "overall_official": {
            "affiliation": "Lund University", 
            "last_name": "Pyotr G Platonov, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Regional Ethical Review Board", 
                "Canada: Comit\u00e9 d'\u00e9thique de la recherche de l'Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary outcome measure in the CASAF study is the number of patients who had relapse of atrial fibrillation during follow up. Primary analysis will be based on assessment the value of the ECG-derived atrial fibrillary rate < vs >= 350 f.p.m. for prediction of atrial fibrillation relapse during follow up", 
            "measure": "Documentation of atrial fibrillation by ECG during follow up period after cardioversion", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "reference": [
            {
                "PMID": "16956916", 
                "citation": "Holmqvist F, Stridh M, Waktare JE, S\u00f6rnmo L, Olsson SB, Meurling CJ. Atrial fibrillatory rate and sinus rhythm maintenance in patients undergoing cardioversion of persistent atrial fibrillation. Eur Heart J. 2006 Sep;27(18):2201-7. Epub 2006 Sep 6."
            }, 
            {
                "PMID": "23515337", 
                "citation": "Choudhary MB, Holmqvist F, Carlson J, Nilsson HJ, Roijer A, Platonov PG. Low atrial fibrillatory rate is associated with spontaneous conversion of recent-onset atrial fibrillation. Europace. 2013 Oct;15(10):1445-52. doi: 10.1093/europace/eut057. Epub 2013 Mar 20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Region Skane", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Region Skane", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}